Anosmia Clinical Trial
Official title:
Effect of Olfactory Training on Olfactory Dysfunction Patients in Hong Kong Population
- Causes of olfactory dysfunction can be classified into conductive and sensorineural causes. - Conductive causes are mainly due to structural nasal problem, which can be treated by nasal surgery - Sensorineural causes included post-infection, post-head injury, post Head and Neck irradiation and other central nervous system diseases. - Olfactory Training is well established treatment for sensorineural olfactory dysfunction in foreign countries. - Olfactory Training by neurological chemosensory stimulation using aromatic substances delivered via electronic portable aromatic rehabilitation (EPAR) diffuser was proved to be effective treatment in COVID-19 related olfactory dysfunction in recent Hong Kong study. - However, there is a lack of local study on the effect of Olfactory Training in other non-COVID-19 sensorineural causes of olfactory dysfunction in Hong Kong population.
Design Prospective double-blinded randomized control trial. Study Period 1/7/2022 - 30/6/2024 for case recruitment. Suitable patient will be recruited. Informed consent will be signed. Objective smell assessment will be done using the University of Pennsylvania Smell Identification Test (UPSIT) and Butanol Threshold Test (BTT). Subjective quality of life score will be obtained by Sino-Nasal Outcome Test (SNOT-22). Subjective smell and taste assessment will be assessed by Visual Analogue Scale (VAS). Patient will be randomized into treatment group and control group using computer generated list by an independent nursing staff. Doctors and the patients will be blinded during the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04964414 -
Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT05445921 -
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
|
Phase 1/Phase 2 | |
| Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
| Withdrawn |
NCT02179554 -
Does Cardiopulmonary Bypass Change Olfaction?
|
||
| Completed |
NCT04957563 -
Clinical Utility of Olfactory Rehabilitation: Treatment for Pacients With Neurosensorial Anosmia
|
N/A | |
| Terminated |
NCT03680911 -
NAC for Head Trauma-induced Anosmia
|
Phase 3 | |
| Completed |
NCT04657809 -
Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia
|
Phase 2 | |
| Completed |
NCT04853836 -
Olfactory Disfunction and Co-ultraPEALut
|
Phase 4 | |
| Recruiting |
NCT05040659 -
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
|
||
| Recruiting |
NCT05562050 -
Characteristics of the Anosmic Olfactory Mucosa
|
||
| Completed |
NCT05152030 -
The Clinical Applicability of the 'TIB' Olfactory Test Device
|
||
| Recruiting |
NCT05384561 -
Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19
|
N/A | |
| Enrolling by invitation |
NCT04764981 -
Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19)
|
N/A | |
| Withdrawn |
NCT04408391 -
Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
|
||
| Completed |
NCT04361474 -
Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
|
Phase 3 | |
| Completed |
NCT03990766 -
Smell Changes & Efficacy of Nasal Theophylline
|
Phase 2 | |
| Completed |
NCT04797936 -
BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19
|
Phase 4 | |
| Recruiting |
NCT04528329 -
Anosmia and / or Ageusia and Early Corticosteroid Use
|
Phase 4 | |
| Completed |
NCT04789499 -
Smell in Covid-19 and Efficacy of Nasal Theophylline
|
Phase 2 | |
| Recruiting |
NCT04384042 -
Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study
|